Carmen S Tellez1, Maria A Picchi2, Daniel Juri2, Kieu Do2, Dhimant H Desai3, Shantu G Amin3, Julie A Hutt2, Piotr T Filipczak2, Steven A Belinsky4. 1. Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM, 87108, USA. ctellez@LRRI.org. 2. Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM, 87108, USA. 3. Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA. 4. Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM, 87108, USA. sbelinsk@LRRI.org.
Abstract
BACKGROUND: Trimethylation of lysine 27 and dimethylation of lysine 9 of histone-H3 catalyzed by the histone methyltransferases EZH2 and G9a impede gene transcription in cancer. Our human bronchial epithelial (HBEC) pre-malignancy model studied the role of these histone modifications in transformation. Tobacco carcinogen transformed HBEC lines were characterized for cytosine DNA methylation, transcriptome reprogramming, and the effect of inhibiting EZH2 and G9a on the transformed phenotype. The effects of targeting EZH2 and G9a on lung cancer prevention was assessed in the A/J mouse lung tumor model. RESULTS: Carcinogen exposure induced transformation and DNA methylation of 12-96 genes in the four HBEC transformed (T) lines that was perpetuated in malignant tumors. In contrast, 506 unmethylated genes showed reduced expression in one or more HBECTs with many becoming methylated in tumors. ChIP-on-chip for HBEC2T identified 327 and 143 genes enriched for H3K27me3 and H3K9me2. Treatment of HBEC2T and HBEC13T with DZNep, a lysine methyltransferase inhibitor depleted EZH2, reversed transformation, and induced transcriptional reprogramming. The EZH2 small molecule inhibitor EPZ6438 also affected transformation and expression in HBEC2T, while a G9a inhibitor, UNC0642 was ineffective. Genetic knock down of EZH2 dramatically reduced carcinogen-induced transformation of HBEC2. Only DZNep treatment prevented progression of hyperplasia to adenomas in the NNK mouse lung tumor model through reducing EZH2 and affecting the expression of genes regulating cell growth and invasion. CONCLUSION: These studies demonstrate a critical role for EZH2 catalyzed histone modifications for premalignancy and its potential as a target for chemoprevention of lung carcinogenesis.
BACKGROUND: Trimethylation of lysine 27 and dimethylation of lysine 9 of histone-H3 catalyzed by the histone methyltransferases EZH2 and G9a impede gene transcription in cancer. Our human bronchial epithelial (HBEC) pre-malignancy model studied the role of these histone modifications in transformation. Tobacco carcinogen transformed HBEC lines were characterized for cytosine DNA methylation, transcriptome reprogramming, and the effect of inhibiting EZH2 and G9a on the transformed phenotype. The effects of targeting EZH2 and G9a on lung cancer prevention was assessed in the A/J mouse lung tumor model. RESULTS: Carcinogen exposure induced transformation and DNA methylation of 12-96 genes in the four HBEC transformed (T) lines that was perpetuated in malignant tumors. In contrast, 506 unmethylated genes showed reduced expression in one or more HBECTs with many becoming methylated in tumors. ChIP-on-chip for HBEC2T identified 327 and 143 genes enriched for H3K27me3 and H3K9me2. Treatment of HBEC2T and HBEC13T with DZNep, a lysine methyltransferase inhibitor depleted EZH2, reversed transformation, and induced transcriptional reprogramming. The EZH2 small molecule inhibitor EPZ6438 also affected transformation and expression in HBEC2T, while a G9a inhibitor, UNC0642 was ineffective. Genetic knock down of EZH2 dramatically reduced carcinogen-induced transformation of HBEC2. Only DZNep treatment prevented progression of hyperplasia to adenomas in the NNK mouse lung tumor model through reducing EZH2 and affecting the expression of genes regulating cell growth and invasion. CONCLUSION: These studies demonstrate a critical role for EZH2 catalyzed histone modifications for premalignancy and its potential as a target for chemoprevention of lung carcinogenesis.
Authors: Tong Ihn Lee; Richard G Jenner; Laurie A Boyer; Matthew G Guenther; Stuart S Levine; Roshan M Kumar; Brett Chevalier; Sarah E Johnstone; Megan F Cole; Kyo-ichi Isono; Haruhiko Koseki; Takuya Fuchikami; Kuniya Abe; Heather L Murray; Jacob P Zucker; Bingbing Yuan; George W Bell; Elizabeth Herbolsheimer; Nancy M Hannett; Kaiming Sun; Duncan T Odom; Arie P Otte; Thomas L Volkert; David P Bartel; Douglas A Melton; David K Gifford; Rudolf Jaenisch; Richard A Young Journal: Cell Date: 2006-04-21 Impact factor: 41.582
Authors: Shuguang Leng; Christine A Stidley; Randy Willink; Amanda Bernauer; Kieu Do; Maria A Picchi; Xin Sheng; Melissa A Frasco; David Van Den Berg; Frank D Gilliland; Christopher Zima; Richard E Crowell; Steven A Belinsky Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Ivo Teneng; Maria A Picchi; Shuguang Leng; Christopher P Dagucon; Suresh Ramalingam; Carmen S Tellez; Steven A Belinsky Journal: DNA Repair (Amst) Date: 2019-04-27
Authors: A P B Moreira; C M Sabarense; C M G C Dias; W Lunz; A J Natali; M B A Glória; M C G Peluzio Journal: Braz J Med Biol Res Date: 2009-11-20 Impact factor: 2.590
Authors: Steven A Belinsky; Donna M Klinge; Christine A Stidley; Jean-Pierre Issa; James G Herman; Thomas H March; Stephen B Baylin Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Rayana L Bighetti-Trevisan; Luciana O Almeida; Larissa M S Castro-Raucci; Jonathan A R Gordon; Coralee E Tye; Gary S Stein; Jane B Lian; Janet L Stein; Adalberto L Rosa; Marcio M Beloti Journal: Biomater Adv Date: 2021-11-13
Authors: Kayla Sompel; Lori D Dwyer-Nield; Alex J Smith; Alamelu P Elango; Lauren A Vanderlinden; Katrina Kopf; Robert L Keith; Meredith A Tennis Journal: Front Oncol Date: 2022-07-18 Impact factor: 5.738